McNeil Consumer Healthcare, Fort Washington, PA 19034, USA.
Clin J Pain. 2012 Mar-Apr;28(3):204-10. doi: 10.1097/AJP.0b013e318227cc4f.
To compare the efficacy of acetaminophen extended release (ER) caplets to placebo in treating muscle soreness after a marathon.
This was a randomized, double-blind, placebo-controlled study of participants ≥ 18 years old, who completed a marathon and experienced muscle soreness rated at least 4 on a 0-to-10 numerical rating scale. The intent-to-treat efficacy analysis included 610 participants. Participants were screened for eligibility before the marathon, and reported to the study tent after the marathon. On confirming eligibility, participants were randomly assigned to 4 days of 3-times-daily treatment of either acetaminophen ER 1300 mg (n=307) or placebo (n=303).
Participants treated with acetaminophen ER reported a significantly (P<0.0001) greater decrease in the primary endpoint of average change from baseline in muscle soreness on the day of the marathon (day 1) (-0.79) than did placebo (-0.36). In addition, the adjusted mean average interference with sleep was significantly lower for acetaminophen ER (2.14) than for placebo (2.52, P=0.0046). The adjusted mean overall satisfaction with treatment was significantly higher for acetaminophen ER (5.38) than for placebo (4.64, P=0.0060). Adverse events were reported by 3.7% of participants, with no clinically important difference between treatment groups. No serious adverse events were reported.
Acetaminophen ER 1300 mg, a nonprescription drug, was an effective treatment for post-race muscle soreness on the day of the marathon. In addition, acetaminophen ER provided benefit for interference with sleep and overall satisfaction with treatment, and was generally well tolerated.
比较对乙酰氨基酚延长释放(ER)胶囊与安慰剂在治疗马拉松赛后肌肉酸痛的疗效。
这是一项针对≥18 岁、完成马拉松并经历至少 4 分(0-10 数字评分量表)肌肉酸痛的参与者的随机、双盲、安慰剂对照研究。意向治疗疗效分析包括 610 名参与者。在马拉松赛前,参与者进行了资格筛选,并在赛后报告至研究帐篷。在确认合格后,参与者被随机分配至 4 天的 3 次/天治疗,分别接受对乙酰氨基酚 ER 1300mg(n=307)或安慰剂(n=303)。
接受对乙酰氨基酚 ER 治疗的参与者报告,在马拉松赛当天(第 1 天)肌肉酸痛的主要终点(平均基线变化)的下降显著更大(P<0.0001)(-0.79),而安慰剂组为-0.36。此外,对乙酰氨基酚 ER 的平均平均睡眠干扰调整后均值明显低于安慰剂(2.14 对 2.52,P=0.0046)。对乙酰氨基酚 ER 的总体治疗满意度调整后均值明显高于安慰剂(5.38 对 4.64,P=0.0060)。3.7%的参与者报告了不良事件,治疗组之间没有明显的临床差异。没有报告严重的不良事件。
非处方药物对乙酰氨基酚 ER 1300mg 是马拉松赛后肌肉酸痛的有效治疗方法。此外,对乙酰氨基酚 ER 对睡眠干扰和整体治疗满意度有好处,且通常耐受性良好。